
may pm et
summari compani spun bristol-my squibb august manufactur orthoped
reconstruct implant fractur manag product dental implant
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
look sale rise
follow rise sale
neg impact on-going suppli chain
constraint price pressur
market expect suppli constraint
continu throughout report
dental surgic sport medicin
foot ankl extrem trauma
account sale see
spine grow mid-singl digit
next two year segment
grow low-singl digit see
knee hip account
sale rebound latter half
expect restor suppli
substanti key brand
zbh adjust oper margin
rang
compani continu remedi
manufactur issu warsaw north
campu facil plant receiv fda
scrutini observ remedi
formerli covidien ceo
replac interim ceo
see ep
think share trade
ep estim
peer near fair valu suppli chain issu
disrupt plagu warsaw
indiana facil led market share
loss think issu mostli price
zbh share price forese issu
mostli resolv although
orthoped surgeri tend sticki
custom extend period zbh
manufactur under-capac could lead
signific market share loss howev
applic knee help drive
sale growth also believ long-term
global demand driver orthoped
popul rise obes level
stake
risk recommend target price
reimburs cut key oversea market
integr challeng
target price
peer ep estim
account suppli chain constraint
risk assess reflect zimmer oper
highli competit industri character rel
short product life cycl requir signific number
new product maintain market share mani custom
reimburs medicar restrict
budgetari environ could result price pressur
howev believ market leadership posit
divers product offer allevi inher
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zimmer biomet form june merger zimmer
hold biomet primarili design develop manufactur market orthoped
reconstruct implant fractur manag product former divis bristol-my squibb
spun sharehold august
zimmer reconstruct implant use restor function lost due diseas trauma joint
knee hip shoulder elbow compani offer wide rang product special knee
total knee m/g unicompartment knee prolong highli crosslink polyethylen
articular surfac materi hip replac product includ versi hip system zmr hip system
trilog acetabular system line specialti hip product compani also continu develop
portfolio minim invas hip replac procedur sell coonrad/morrey product line
elbow replac implant product along line restor dental product
spine trauma area compani sell devic use reattach stabil damag bone
tissu support bodi natur heal process common stabil bone fractur
concern intern fixat bone fragment involv use assort plate
screw rod wire pin offer line product design use fractur fixat octob
compani acquir spinal busi abbott lab million cash
make market orthoped surgic product use surgeon orthoped well
non-orthoped procedur product includ tourniquet blood manag system wound
de-bridg product power surgic instrument pain manag devic orthoped soft
good provid support and/or heat retent compress trauma knee ankl back
upper extrem includ shoulder elbow neck wrist
competit landscap zimmer oper competit global market success often due
technolog innov product qualiti brand reput custom relationship servic
factor heighten barrier entri competit high among exist particip
well capit larg experienc sale forc within global market orthoped devic
zimmer compet johnson johnson stryker smith nephew
spinal implant categori compani compet princip
impact major develop june zimmer acquir biomet transact valu
billion connect transact zimmer chang name zimmer biomet ticker
symbol new york stock exchang chang zmh combin compani leader
musculoskelet market juli zimmer acquir ldr hold billion ldr medic
devic compani focus proprietari surgic technolog treatment patient suffer
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
bullish sinc may technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu view mani product
categori histor recession-resist
expect continu grow growth
procedur rate area view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped steadili improv
see continu recoveri
medic devic tax requir
healthcar reform law went effect
januari temporarili suspend
januari
congress pass stopgap measur includ
suspend medic devic tax anoth
two year tax
slate becom effect januari
decemb congress pass tax cut
job act includ repeal
individu mandat compon
afford act requir
peopl health insur pay fine
effect januari believ repeal
individu mandat result fewer
insur peopl neg impact
equip sub-industri fewer insur
patient would like lead fewer procedur
anticip hospit
largest buyer medic equip would also
advers impact could
pressur sub-industri
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
pressur lower demand certain product
categori affect sale growth also think
 hospit becom cautiou
regard capit budget amid shift
base index
five-year market price perform may
procedur inpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
 composit index year
date april health
declin composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
account price pressur on-going improv suppli
chain constraint expect suppli chain issu resolv set
ep estim ep vs ahead
estim sale rose improv knee hip busi
sale continu strength unit guid sale growth
includ advers fx ep /jeffrey loo
analyst research note compani news
hold inc keep target
below-p ep estim reflect
on-going effort remedi violat key plant highlight fda
initi novemb ep vs higher
estim lower ep ep estim
sale increas billion
constant currenc basi decreas except
product categori grew product line experienc
constant-curr revenu declin low-singl digit encourag
ceo effort make chang leadership build better cultur
could reduc risk face futur complianc issu
hand fda addit observ late-april
inspect ceo comment go two-year
hold inc keep target
below-p ep estim set ep
ep vs line view sale rose
knee hip believ new ceo hanson face
challeng tackl qualiti issu warsaw plant suppli chain
constraint result market share loss believ longer
issu continu difficult regain market share think new
product launch includ robot applic knee help drive
hold inc lower target price
below-p forward ep estim see
continu suppli chain challeng advers impact sale market share
think capac issu warsaw plant continu
could put share risk ep vs
estim lower ep estim
sale fell knee product hip
 sale rose knee sale hurt lower price
buy keep target price below-p
forward ep estim ep vs
estim lower ep estim
cfo daniel florin serv interim ceo
follow resign david dvorak earlier month sale rose
aid inclus ldr hold knee hip sale
 sale rose believ remain constrain
suppli chain issu disrupt warsaw facil /jeffrey loo
hold inc keep target
peer ep estim ep
vs estim lower ep
sale rose knee sale hip
continu advers impact suppli constraint product remain
interrupt warsaw facil think on-track restor
adequ suppli acceler growth updat sale
guidanc growth ep
biomet hold keep target
peer revis ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
